• Sign In
  • FAQ
  • Create an Account
  • 866-930-6790
Currency
USD
Toggle Nav
My Cart
Search
Menu
Account
Settings
Currency
USD

Cell Cycle

Items 1-50 of 387

Page
per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Product Citation
  1. A10004
    MLN8237 (Alisertib)

    Aurora A Kinase inhibitor

    MLN8237 (Alisertib) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3..
    Quick View
  2. A10093
    AT7519

    CDK Inhibitor

    AT7519 is an inhibitor of multiple cyclin-dependent kinases (CDKs), which may result in cell cycle arrest, induction of apoptosis, and inhibition of tumor cell proliferation.
    Quick View
  3. A10095
    AT9283

    Aurora/JAK inhibitor

    AT9283 inhibits aurora kinase A and B and targets other tyrosine and serine/threonine kinases associated with myeloid cell proliferation.
    Quick View
  4. A10100
    TC-S 7010 (Aurora A Inhibitor I)

    Aurora A Inhibitor

    Aurora A Inhibitor I is a potent and selective inhibitor of Aurora A kinase (AurA), with IC50 values to be 3.4 nM (Aurora A) and unusually high selectivity 1000 fold against Aurora B; a useful tool compound for investigating the cellular role of Aurora A kinases.

    Quick View
  5. A10107
    Azathioprine

    Azathioprine is an immunosuppressive drug, inhibiting purine synthesis and GTP-binding protein Rac1 activation, used in the treatment of organ transplantation and autoimmune diseases.
    Quick View
  6. A10109
    AZD1152-HQPA (Barasertib)

    Aurora Kinase B inhibitor

    AZD 1152-HQPA is a highly potent and selective inhibitor of Aurora B, with Ki values to be 0.36 (Aurora B) and 1369 nM (Aurora A) respectively and has a high specificity versus a panel of 50 other kinases.
    Quick View
  7. A10113
    AZD7762

    Chk1 & Chk2 inhibitor

    AZD7762 is a potent ATP-competitive checkpoint kinase inhibitor that drives checkpoint abrogation and potentiates DNA-targeted therapies.
    Quick View
  8. A10134
    BI 2536

    PLK inhibitor

    BI 2536 is a selective inhibitor of Plk1, which inhibits Plk1 enzyme activity at low nanomolar concentrations.
    Quick View
  9. A10135
    BI6727 (Volasertib)

    PLK Inhibitor

    BI6727 is a highly potent and selective polo-like kinase (PLK) 1 inhibitor (enzyme IC50 = 0.87 nM, EC50 = 11-37 nM on a panel of cancer cell lines).
    Quick View
  10. A10163
    BS-181

    CDK inhibitor

    BS-181 is a potential anti-tumor agent as CDK7 inhibitor.
    Quick View
  11. A10184
    CCT129202

    Aurora Inhibitor

    CCT129202 is a representative of a structurally novel series of imidazopyridine small-molecule inhibitors of Aurora kinase activity. It shows high selectivity for the Aurora kinases over a panel of other kinases tested and inhibits proliferation in multiple cultured human tumor cell lines.

    Quick View
  12. A10248
    CYC116

    Aurora Kinase inhibitor

    Aurora kinase/VEGFR 2 inhibitor CYC116 inhibits Aurora kinases A and B and vascular endothelial growth factor receptor 2 (VEGFR2), resulting in disruption of the cell cycle, rapid cell death, and the inhibition of angiogenesis.
    Quick View
  13. A10352
    ENMD-2076

    Aurora A / FLT3 Inhibitor

    ENMD-2076 has selective activity against Aurora A and Flt3 with IC50 of 14 nM and 1.86 nM, 25-fold selective for Aurora A than over Aurora B and less potent to VEGFR2/KDR and VEGFR3, FGFR1 and FGFR2 and PDGFRα. Phase 2.
    Quick View
  14. A10381
    Fasudil HCl (HA-1077)

    ROCK inhibitor

    Fasudil HCl is a cyclic nucleotide-dependent protein kinase inhibitor and Rho-associated kinase inhibitor (IC50 = 10.7 μM).
    Quick View
  15. A10390
    Flavopiridol (Alvocidib)

    CDK inhibitor

    Flavopiridol (Alvocidib) is a cyclin-dependent kinase inhibitor under clinical development for the treatment of chronic lymphocytic leukemia.
    Quick View
  16. A10441
    GSK429286A

    ROCK Inhibitor

    GSK429286A is a cell-permeable, selective small molecule inhibitor of Rho-associated, coiled-coil containing protein kinase (ROCK).
    Quick View
  17. A10442
    GSK461364

    PLK Inhibitor

    GSK461364 is an ATP-competitive inhibitor of polo-like kinase 1 (Plk1).
    Quick View
  18. A10448
    Hesperadin

    Aurora B Kinase inhibitor

    Hesperadin is a human Aurora B inhibitor with an IC50 of 40 nM for the prevention of the phosphorylation of substrate. It markedly reduces the activity of AMPK, Lck, MKK1, MAPKAP-K1, CHK1 and PHK while it does not inhibit MKK1 activity in vivo.
    Quick View
  19. A10452
    HMN-214

    PLK Inhibitor

    HMN-214 inhibits polo-like and cyclin-dependent kinase activity, has potent antimicrotubular effects and results in profound apoptosis and antitumor activity in a broad spectrum of human xenografts.
    Quick View
  20. A10471
    Indirubin

    CDK & GSK-3β inhibitor

    Indirubin, the active constituent of a Chinese antileukaemia medicine, is a potent cyclin-dependent kinases and GSK-3β inhibitor with IC50 of about 5 μM and 0.6 μM.
    Quick View
  21. A10494
    JNJ-7706621

    CDK/Aurora A/B Inhibitor

    JNJ-7706621 is pan-CDK inhibitor with the highest potency on CDK1/2 with IC50 of 9 nM/4 nM and showing >6-fold selectivity for CDK1/2 than CDK3/4/6 in cell-free assays. It also potently inhibits Aurora A/B and has no activity on Plk1 and Wee1.
    Quick View
  22. A10508
    KW-2449

    FLT3/FGFR/Bcr-Abl/Aurora Inhibitor

    KW-2449 is a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase.
    Quick View
  23. A10599
    MK-1775

    WEE1 Inhibitor

    MK-1775 is a potent and selective Wee1 kinase inhibitor in vitro and in vivo.
    Quick View
  24. A10601
    MLN8054

    Aurora A Inhibitor

    MLN8054 is an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo.
    Quick View
  25. A10673
    (E/Z)-Rigosertib sodium ((E/Z)-ON-01910 sodium)

    PLK Inhibitor

    ON-01910 is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress.
    Quick View
  26. A10701
    PD 0332991 HCl (Palbociclib)

    CDK 4/6 inhibitor

    PD 0332991 HCl is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity.
    Quick View
  27. A10714
    PHA-680632

    Aurora inhibitor

    PHA-680632 is potent inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 27 nM, 135 nM and 120 nM, respectively. It has 10- to 200-fold higher IC50 for FGFR1, FLT3, LCK, PLK1, STLK2, and VEGFR2/3.
    Quick View
  28. A10715
    Danusertib (PHA-739358)

    Aurora inhibitor

    Danusertib (PHA-739358) is an Aurora kinase inhibitor for Aurora A/B/C with IC50 of 13 nM/79 nM/61 nM in cell-free assays, modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc. Phase 2
    Quick View
  29. A10716
    PHA-793887

    CDK Inhibitor

    PHA-793887, a novel potent inhibitor of Cdk, target on kinds of cyclin-dependent kinase under low concentrations and poses high activity against several cancer cell lines.
    Quick View
  30. A10806
    Roscovitine (Seliciclib)

    CDK Inhibitor

    Roscovitine (Seliciclib) is a CDK inhibitor that preferentially inhibit multiple enzyme targets including CDK2, CDK7 and CDK9.
    Quick View
  31. A10850
    SNS-032 (BMS-387032)

    CDK inhibitor

    SNS-032 (BMS-387032) is a highly selective and potent inhibitor of cyclin-dependent kinases (Cdks) 2, 7, and 9, with in vitro growth inhibitory effects and ability to induce apoptosis in malignant B cells.
    Quick View
  32. A10851
    SNS-314

    Aurora inhibitor

    SNS-314 Mesylate is a potent and selective inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 9 nM, 31 nM, and 3 nM, respectively. It is less potent to Trk A/B, Flt4, Fms, Axl, c-Raf and DDR2. Phase 1.
    Quick View
  33. A10884
    TAME

    APC/C inhibitor

    TAME is a small molecule anaphase-promoting complex/cyclosome (APC) inhibitor with an IC50 of 12 μM.
    Quick View
  34. A10899
    RKI-1313

    ROCK inhibitor

    RKI-1313 is a negative control for RKI-1447 which is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer.
    Quick View
  35. A10928
    Thiazovivin

    ROCK inhibitor

    Thiazovivin is a selective inhibitor of Rho-associated kinase (ROCK).
    Quick View
  36. A10981
    VX-680 (MK-0457, Tozasertib)

    Aurora Kinase inhibitor

    VX-680 is a potent and selective small-molecule inhibitor of the Aurora kinases.
    Quick View
  37. A11001
    Y-27632 2HCl

    ROCK Inhibitor

    Y-27632 is a Rho-Associated Coil Kinase (ROCK) inhibitor that increases the cloning efficiency of human embryonic stem cells (hESCs).
    Quick View
  38. A11009
    ZM-447439

    Aurora Kinase inhibitor

    ZM 447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively. It is more than 8-fold selective for Aurora A/B than MEK1, Src, Lck and has little effect against CDK1/2/4, Plk1, Chk1, etc.
    Quick View
  39. A11010
    Zoledronic Acid

    osteoclastic bone resorption inhibitor

    Zoledronic acid is a bisphosphonate which used to multiple myeloma and prostate cancer treament.
    Quick View
  40. A11034
    A-674563

    Akt inhibitor

    A-674563 is a B/Akt inhibitor with an IC50 of 14 nM and also shows inhibitory activity against PKA and CDK2 with IC50 of 16 and 46 nM, respectively.
    Quick View
  41. A11036
    LY2603618 (IC-83)

    Chk inhibitor

    LY2603618 is a chk2 inhibitor that binds to and inhibits the activity of chk2, which may prevent the repair of DNA caused by DNA-damaging agents.
    Quick View
  42. A11045
    Flavopiridol HCl

    CDK inhibitor

    Flavopiridol HCl is an inhibitor of cyclin-dependent kinases. The (-)-cis form induces apoptosis in particular tumor cells.
    Quick View
  43. A11046
    CHIR-124

    CHK Inhibitor

    CHIR-124 is a novel and potent Chk1 inhibitor (IC50: 0.32 nM and 697 nM for Chk1 and Chk2 respectively).
    Quick View
  44. A11047
    PHA-848125 (Milciclib)

    CDK Inhibitor

    PHA-848125 (Milciclib) is an orally bioavailable inhibitor of CDKs and TRKA with potential antineoplastic activity.
    Quick View
  45. A11066
    AMG 900

    Aurora Kinase inhibitor

    AMG 900 is a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.
    Quick View
  46. A11067
    TAK-901

    Aurora Kinase A/B inhibitor

    TAK-901 is a novel inhibitor of Aurora A/B with IC50 of 21 nM/15 nM. It is not a potent inhibitor of cellular JAK2, c-Src or Abl. Phase 1.
    Quick View
  47. A11081
    CCT137690

    Aurora Kinase inhibitor

    CCT137690 is a highly selective inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 15 nM, 25 nM and 19 nM. It has little effect on hERG ion-channel.
    Quick View
  48. A11105
    AZD5438

    CDK inhibitor

    AZD5438 is a potent inhibitor of cyclin-dependent kinase (CDK) 1, 2 and 9 (IC50 values are 16, 6 and 20 nM respectively).
    Quick View
  49. A11108
    CCT241533

    Chk2 inhibitor

    CCT241533 is a potent and selective Inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors.
    Quick View
  50. A11129
    Dinaciclib (SCH 727965)

    CDK Inhibitor

    Dinaciclib (SCH 727965) is a potent and selective cyclin-dependent kinase (CDK) inhibitor, selectively inhibiting CDK1, CDK2, CDK5 and CDK9 with IC50 values of 3, 1, 1 and 4 nM respectively.
    Quick View

Items 1-50 of 387

Page
per page
Set Descending Direction
Shop By
Shopping Options
Category
Actions
  1. Inhibitor 363 items
  2. Agonist 2 items
  3. Antagonist 4 items
  4. Activator 2 items
  5. Modulator 1 item
  6. Degrader 3 items
  7. Stabilizer 2 items
  8. Ligand 2 items
On sale
  1. Yes 2 items
Price
  1. $0.00 - $1,000.00 386 items
  2. $1,000.00 - $2,000.00 1 item
Target
  1. STK 1 item